Study wrapper · #1088
PYY3-36 potentiates Semaglutide-mediated mitochondrial modulation in MASLD.
Geiger N, Nickel AG, Kohlhaas M, et al. American journal of physiology. Endocrinology and metabolism. 2026.
DOI: 10.1152/ajpendo.00036.2026PubMed: 42526426
Editor's note
This controlled rodent study reports that semaglutide, alone and combined with PYY3-36, is associated with reduced hepatic inflammation and improved mitochondrial measures in a MASLD model. As preclinical work, the mechanistic findings should not be extrapolated to humans without clinical confirmation. The additive effect beyond food restriction is a noteworthy early signal for combination approaches.
Plain-language abstract
In obese rats fed a fatty, high-fructose diet, semaglutide and the gut hormone PYY3-36 each reduced liver inflammation and fatty-liver severity, with additive benefits when combined. The combination also improved markers of mitochondrial function beyond what weight loss alone achieved.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026